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Abstract 
Extended spectrum β-lactamases (ESBLs) are enzymes that capable of destroying the antibiotics of β-
lactam, and cephalosporin, and Metallo-β-lactamase enzymes (MBL) can also deactivate all β-lactams 
and carbapenems. This study aimed to determine ESBLs and MBLs enzymes and the frequency of 
NDM-1 gene. In this study, 200 Escherichia coli isolates of women with urinary tract infection were 
collected (100 inpatients and 100 outpatients). Minimum inhibitory concentration (MIC) for 
ceftazidime and meropenem was determined by E-test. A phenotypic confirmation test was used to 
detect ESBL enzymes. MBLs production was performed with modified Hodge test (MHT) and EDTA 
disk synergy (EDS) test. PCR was used for detecting the presence of NDM-1 gene. From 200 isolates, 
93 isolates produce ESBL enzymes. Overall, 97 isolates were resistant to ceftazidime, and 38 isolates 
resistant to meropenem. The results of the MHT and EDS positive tests were 41 and 16 isolates, 
respectively. NDM-1 was not found in any of the patients. The prevalence of E. coli isolates producing 
both ESBLs and MBLs enzymes, is a serious threat to clinical infections. Accordingly, for the control 
and treatment of these strains, rapid and accurate identification can be greatly helpful. 
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1. Introduction 
One of the most important infections that affect 
parts of the urinary tract is urinary tract infection 
(UTI). Bacteria are the main reason for this infection. 
The most common bacterial cause for UTI is 
Escherichia coli. UTIs report about 150 million cases 
each year and are more common in women than men 
[1-3]. Up to 10% of women have a UTI in a given year, 
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and half of them have at minimum one infection at 
some point in their lifetime [4]. There is a rising worry 
for multidrug-resistant bacteria that produce 
extended-spectrum β-lactamases (ESBLs). E. coli 
becomes progressively resistant to expanded-
spectrum cephalosporins by the production of ESBLs 
[5,6]. Class D β-lactamases or oxacillinases (OXA) are 
commonly distributed between clinically relate Gram-
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negative bacteria [7,8]. Carbapenem antibiotics are 
now used to treat infections caused by β-lactam 
resistant bacteria [2,9]. This antibiotic is used to treat 
infections caused by penicillin or cephalosporin-
resistant Gram-negative bacilli because this antibiotic, 
in addition to a broad spectrum of action, has 
acceptable stability against most β-lactamase [2,10,11]. 
Resistance to carbapenem is mainly created with 
Metallo-β-lactamases (MBL) such as NDM (New 
Delhi Metallo-β-lactamase), a class B type of β-
lactamases that know bivalent metal ions [12,13]. 
Recently, a new MBL named NDM-1 appeared in E. 
coli [14,15]. This gene causes resistance to penicillins, 
cephalosporins, and carbapenems [16]. This study 
aimed to determine ESBL, and MBL production 
ability and determination of the frequency of NDM 
gene in E. coli strains isolated from UTI in women. 
 
2. Materials and Methods 
2.1 Bacterial strain collection and identification  
In this descriptive-analytical study, 200 E. coli 
isolates with urinary tract infection were collected 
from women with UTI in two groups of inpatients 
(n=100) and outpatients (n=100) in teaching hospitals 
from Shahrekord, Iran from 2016 to 2017. In this 
study, patients who were diagnosed with UTI 48-72 
hours after hospitalization were considered as 
inpatient samples. Patients who have not been 
hospitalized in the past month were also used as 
outpatient samples. Isolates were detected using 
standard tests including Gram stain, microscopy 
analysis and culture in EMB media, MacConkey agar, 
and Blood agar (Merck, Germany), and other 
biochemical tests. 
 
2.2 Determination of MIC and ESBL production 
The minimum inhibitory concentration (MIC) 
test was done by the Epsilon test (E-test) of Liofilchem 
Company (Italy) with a concentration range of 0.002-
32 μg/mL to meropenem and ceftazidime. Evaluation 
and determination of inhibition zones were performed 
after culturing and incubating the plates at 37 °C 
overnight, using the CLSI guidelines. The phenotypic 
combined disc method was also used to determine 
ESBL enzymes [8]. E. coli ATCC 25922 and Klebsiella 
pneumonia ATCC 1705 were considered as negative 
and positive controls. 
 
2.3 MHT and EDS test 
In this study modified Hodge test (MHT) and 
EDTA disk synergy test (EDS) were performed to 
detect MBLs enzymes. Further, E. coli ATCC 25922 
and Klebsiella pneumonia ATCC1705 were 
considered as negative and positive controls for 
running MHT, respectively [17,18].   
 
2.4 DNA extraction and PCR 
At this stage, after culturing samples on media, 
DNA was extracted using the boiling method [8]. The 
Single-PCR technique was also used to detect NDM-1 
and 16s rRNA genes. Primers for this study are shown 
in Table 1 [19-21]. The presence of the 16srRNA gene 
(internal gene for E. coli) was investigated to approve 
the phenotypic tests for E. coli detection. 
 
2.5 Statistical analysis  
The statistical analysis was performed using SPSS, 
version 23.0 (SPSS IBM, NY, USA). The results are 





In this study, the age range of patients was 2-88 
years. The maximum and minimum prevalence of 
isolates were allocated to the internal wards and 
intensive care units (ICU) respectively. In this study, 
the result of resistance to ceftazidime was 73% for 
inpatients and 25% for outpatients.  Resistance to 
meropenem was 28% for inpatients and 10% for 
outpatients. From 100 isolates from inpatients, 70 
isolates (70%), and from 100 isolates from outpatients, 
23 (23%) isolates produce ESBLs. The results of the 
MHT and EDS tests were positive in 21% and 20% of 
inpatient samples and 8% and 8% of outpatient 
samples, respectively. After the electrophoresis of PCR 




Table 1. Primers used in this study 
 
Target Primer sequence (5' to 3') Size 
(bp) 
NDM-F    GGTTTGGCGATCTGGTTTTC 
624 bp 
NDM-R    CGGAATGGCTCATCACGATC 
16s rRNA-F   AGGCCTTCGGGTTGTAAAGT 
420 bp 
16s rRNA-R   ACCTCCAAGTCGACATCGTT 
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Resistant E. coli is considered a health-
threatening pathogen and causes many diseases in 
humans, especially those with underlying diseases and 
immune deficiencies. The infections owing to E. coli 
are treated with broad-spectrum antibiotics [22-24]. 
Antibiotic resistance in these bacteria is increasing and 
is spreading all over the world [2]. Carbapenem and β-
lactam antibiotics are drugs of choice for E. coli 
infections. It is very valuable to early detection of ESBL 
and MBL in bacteria to control and prevent the spread 
of resistance strain in society and hospitals. These 
results and information can lead to a proper prognosis 
and selection of the appropriate medication by the 
physician [25,26]. We observed that 93 isolates 
produce ESBL enzymes. Also, 97 isolates resistance to 
ceftazidime and 38 isolates resistance to meropenem. 
NDM gene was not funded in the patients. In a similar 
study, in Pakistan, it was observed that among 116 E. 
coli isolates from UTIs, 98 isolates were resistant to 
meropenem and imipenem and a total of 66 isolates 
were found to be ESBL producers [27]. A study in 
India showed that imipenem and ceftazidime 
resistance in clinical isolates of E. coli were 9%, and 
62.1%, respectively. They also showed 61.1% of E. coli 
isolates were ESBLs [28]. Jamil et al. from Pakistan 
reported that among 25 carbapenem-resistant E. coli, 
16% contained MBL by phenotypic test [29]. In 
another study by Qamar et al. of 100 E. coli isolates, 
81% were MBL producers and 18.4% were NDM-1 
positive [30]. In a similar study by Koraei et al. from 
southwest of Iran, in 376 E. coli isolates, NDM-1gene 
was not found in any isolates [31].  
In this study, we had some limitations. The main 
limitations were the study of two medical centers and 
the small sample size.  
The emergence and spread of antibiotic resistance 
by ESBL and MBL producer isolates have been a 
global problem that indicates the excessive use of 
antibiotics. These types of antibiotic resistance are a 
serious problem in clinical therapeutic selections in the 
hospital as well as in the community. So, it is necessary 
to report ESBL/MBL production along with the daily 
sensitivity reporting, which will help the clinicians in 
determining correct antibiotics. 
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